Mosby Periodicals Home Visit
ASCPT
Search User
Pref
Help
CPT Home Current
Issue
All
Issues
Order About this
Journal
<<
Issue
>>
Issue

March 2003 Volume 73 Number 3


Pharmacokinetics and Drug Disposition
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

Michael H. Skinner, MD, PharmD [MEDLINE LOOKUP]
Han-Yi Kuan, PhD [MEDLINE LOOKUP]
Alan Pan, MB, BCh, BAO [MEDLINE LOOKUP]
Korbtham Sathirakul, PhD [MEDLINE LOOKUP]
Mary Pat Knadler, PhD [MEDLINE LOOKUP]
Celedon R. Gonzales, MS [MEDLINE LOOKUP]
Kwee Poo Yeo, PhD [MEDLINE LOOKUP]
Shobha Reddy, BS [MEDLINE LOOKUP]
Maggie Lim, RPh [MEDLINE LOOKUP]
Mosun Ayan-Oshodi, MS [MEDLINE LOOKUP]
Stephen D. Wise, FRCP [MEDLINE LOOKUP]
Indianapolis, Ind, and Singapore
Previous article in Issue
Next article in Issue
View full-text version
View print version (PDF)
Drug links from Mosby's DrugConsult
Genetic information from OMIM
Citation of this Article
    View on PubMed
    Download in citation manager format
    Download in Medlars format
Related articles in PubMed

   Abstract  TOP 

Background and Objectives: Duloxetine, a potent dual reuptake inhibitor of serotonin and norepinephrine currently undergoing clinical investigation for treatment of depression and stress urinary incontinence, has the potential to act as both a substrate and an inhibitor of cytochrome P4502D6 (CYP2D6). Our objectives were to determine the effect of duloxetine on the pharmacokinetics of desipramine, a tricyclic antidepressant metabolized by CYP2D6 (study 1), and the effect of paroxetine, a potent CYP2D6 inhibitor, on duloxetine pharmacokinetics (study 2).
Methods: Subjects were healthy men and women between 21 and 63 years old. All subjects were genotypically CYP2D6 extensive metabolizers. In study 1, 50 mg of desipramine was administered as a single dose alone and in the presence of steady-state duloxetine 60 mg twice daily. In study 2, steady-state pharmacokinetics of duloxetine 40 mg once daily were determined in the presence and absence of steady-state paroxetine 20 mg once daily.
Results: Duloxetine increased the maximum plasma concentration of desipramine 1.7-fold and the area under the concentration-time curve 2.9-fold. Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold. Reports of adverse events were similar whether duloxetine was administered alone or in combination with desipramine or paroxetine.
Conclusion: Duloxetine 60 mg twice daily is a moderately potent CYP2D6 inhibitor, intermediate between paroxetine and sertraline. The potent CYP2D6 inhibitor paroxetine has a moderate effect on duloxetine concentrations. The results of these 2 studies suggest that caution should be used when CYP2D6 substrates and inhibitors are coadministered with duloxetine. (Clin Pharmacol Ther 2003;73:170-7.)


   Publishing and Reprint Information  TOP